摘要
目的分析抗癫痫药物(AEDs)临床疗效与血药浓度之间的关系,为临床合理用药提供个体化用药参考,探讨如何开展抗癫痫类药血药浓度监测后的药学服务。方法采用酶扩增均相免疫分析法(EMIT)监测抗癫痫类药物丙戊酸钠(VPA)、苯妥英钠(PHT)、卡马西平(CBZ)血药浓度,回顾性调查、统计分析2009-2011年945例次VPA、278例次PHT、157例次CBZ血药浓度监测结果。结果其中55.3%的患者VPA监测结果在有效参考血药浓度范围以内,31.7%的患者PHT监测结果在有效血药浓度范围以内,79.0%的患者CBZ监测结果在有效参考血药浓度范围内。结论抗癫痫药物血药浓度监测是临床用药的依据之一,临床药师于血药浓度监测后为患者提供个体化给药建议,对合理用药有重要的指导意义。
Objective To analyze the relationship between the clinical effect and serum concentrations of the antiepileptic drugs （AEDs）, and to provide reference for individualized treatment. Methods EMIT method was used to determine the serum concentration of valproic acid （VPA）, phenytoin （PHT）, carbamazepine （CBZ）. The serum concentration monitoring records of VPA （945 cases）, PHT （278 cases）, CBZ （157 cases） were retrospectively investigated and statistically analyzed. Results The proportions of VPA, PHT, CBZ in effective serum concentration range were 55.3%, 31.7%, 79.0%, respectively. Conclusion Serum concentration monitoring of antiepileptic drug is the basis for clinical medication, which is of great significance to the rational use of drugs.
出处
《海南医学》
CAS
2012年第21期106-107,共2页
Hainan Medical Journal
